Clinical Trial: An Open-Label Study Evaluating the Safety, Tolerability, and Preliminary Clinical Activity of Cizutamig in Patients with Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease (SARD-ILD) (China)

China, Aug. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An Open-Label Study Evaluating the Safety, Tolerability, and Preliminary Clinical Activity of Cizutamig in Patients with Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease (SARD-ILD)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130777

Registration Time: 2026/08/24

Type: Interventional study

Primary Sponsor: Peking University First Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=321076

Published by HT Digital Content Services with permission from Health Daily Digest....